AMENDMENTS TO THE CLAIMS

1-34. (canceled)

35. (currently amended) A pharmaceutical composition comprising:

a therapeutically effective amount of cilostazol ;

a solubilizer selected from the group consisting of polyoxyl 40 castor oil, polyoxyl 35 castor oil, PEG-8 caprylic/capric glycerides, sorbitan monooleate, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprate, caprylic acid monoglycerides, caprylic acid [/]diglycerides, and monoacetylated monoglycerides[-] and diacetylated monoglycerides, linoleoyl monoglycerides, lauroyl macrogol-32 glycerides, α-tocopherol, α-tocopherol acetate, α-tocopherol succinate, α-tocopherol polyethyleneglycol ~~(200-8000 MW)~~ succinate, α-tocopherol polyethylene glycol 400 succinate, d1-α-tocopherol polyethyleneglycol 1000 succinate, and d-α-tocopherol polyethyleneglycol 1000 succinate;

[;] and

a release modulator which synchronizes the release of the cilostazol and the solubilizer,

wherein the release modulator is selected from the group consisting of methyl cellulose, a hydroxypropyl methylcellulose derivative, an acrylic polymer, a polyvinylpyrrolidone copolymer, a polyvinyl acetyl phthalate, a high molecular weight polysaccharide gum, hydrogenated vegetable oil, glycerol dibehenate, glycerol mono stearate, glycerol distearate, α-tocopherol succinate, α-tocopherol polethyleneglycol succinate, sucrose distearate, cetyl ester wax, and mixtures thereof;

wherein the cilostazol is from 0.5% to 50% w/w of the composition and at least 95 wt% of the cilostazol is suspended in the composition, the solubilizer is present from 15% w/w to 95% w/w of the composition, ~~and~~ the release modulator is from 1% to 50% w/w of the composition; and wherein the cilostazol is released over an extended period of time.

36-41. (canceled)

42-46. (canceled)

47. (canceled)

48. (currently amended) The pharmaceutical composition of claim 35~~47~~, wherein the period of time is more than 1 hour.

49. (previously presented) The pharmaceutical composition of claim 48, wherein the period of time is more than 2 hours.

50. (previously presented) The pharmaceutical composition of claim 49, wherein the period of time is from 2 hours to 24 hours.

51. (previously presented) The pharmaceutical composition of claim 35, wherein the release of cilostazol and solubilizer are synchronized with a correlation coefficient of greater than 0.80.

52. (original) The pharmaceutical composition of claim 35 including one or more additives.

53. (canceled)

54. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is d-α-tocopherol polyethylene glycol 1000 succinate and the release modulator is α-tocopherol succinate.

55. (original) The pharmaceutical composition of claim 54 including one or more additives.

56. (original) The pharmaceutical composition of claim 55, wherein the solubilizer is d-α-tocopherol polyethylene glycol 1000 succinate, the release modulator is α-tocopherol succinate and the additive is polyethylene glycol.

57. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is hydroxypropylmethylcellulose.

58. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is glycerol dibehenate, glycerol palmitostearate, glycerol distearate, or mixtures thereof.

59. (currently amended) An oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer selected from the group consisting of polyoxyl 40 castor oil, polyoxyl 35 castor oil, PEG-8 caprylic/capric glycerides, sorbitan monooleate, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprate, caprylic acid monoglycerides, caprylic acid [/]diglycerides, and monoacetylated monoglycerides[-] and diacetylated monoglycerides, linoleoyl monoglycerides, lauroyl macrogol-32 glycerides, α-tocopherol, α-tocopherol acetate, α-tocopherol succinate, α-tocopherol polyethyleneglycol ~~(200-8000 MW)~~ succinate, α-tocopherol polyethylene glycol 400 succinate, d1-α-tocopherol polyethyleneglycol 1000 succinate, and d-α-tocopherol polyethyleneglycol 1000 succinate; and

a release modulator which synchronizes the release of the cilostazol and the solubilizer wherein the release modulator is selected from the group consisting of methyl cellulose, a hydroxypropyl methylcellulose derivative, an acrylic polymer, a polyvinylpyrrolidone copolymer, a polyvinyl acetyl phthalate, a high molecular weight polysaccharide gum, hydrogenated vegetable oil, glycerol dibehenate, glycerol mono stearate, glycerol distearate, α-tocopherol succinate, α-tocopherol polethyleneglycol succinate, sucrose distearate, cetyl ester wax, and mixtures thereof;

wherein the cilostazol is from 0.5% to 50% w/w of the composition and at least 95 wt% of the cilostazol is suspended in the composition, the solubilizer is present from 15% w/w to 95% w/w of the composition, ~~and~~ the release modulator is from 1% to 50% w/w of the composition and wherein the cilostazol is released over an extended period of time.

60. (currently amended) A solid oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer which synchronizes the release of the cilostazol and itself, said solubilizer being selected from the group consisting of polyoxyl 40 castor oil, polyoxyl 35 castor oil, PEG-8 caprylic/capric glycerides, sorbitan monooleate, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprate, caprylic acid monoglycerides, caprylic acid [/]diglycerides, and monoacetylated monoglycerides[-] and diacetylated monoglycerides, linoleoyl monoglycerides, lauroyl macrogol-32 glycerides, α-tocopherol, α-tocopherol acetate, α-tocopherol succinate, α-tocopherol polyethyleneglycol ~~(200-8000 MW)~~ succinate, α-tocopherol

polyethylene glycol 400 succinate, d1-α-tocopherol polyethyleneglycol 1000 succinate, and d-α-tocopherol polyethyleneglycol 1000 succinate; and

a release modulator selected from the group consisting of methyl cellulose, a hydroxypropyl methylcellulose derivative, an acrylic polymer, a polyvinylpyrrolidone copolymer, a polyvinyl acetyl phthalate, a high molecular weight polysaccharide gum, hydrogenated vegetable oil, glycerol dibehenate, glycerol mono stearate, glycerol distearate, α-tocopherol succinate, α-tocopherol polethyleneglycol succinate, sucrose distearate, cetyl ester wax, and mixtures thereof;

wherein the cilostazol is from 0.5% to 50% w/w of the composition and at least 95 wt% of the cilostazol is suspended in the composition, the solubilizer is present from 15% w/w to 95% w/w of the composition, ~~and~~ the release modulator is from 1% to 50% w/w of the composition and wherein the cilostazol is released over an extended period of time.[.]

61. (original) The dosage form of claim 60, wherein the dosage form is a capsule.

62-64. (canceled)

65. (previously presented)The pharmaceutical composition of claim 35, wherein the release modulator is the same compound as the solubilizer.

66-71. (canceled)

72. (currently amended) The dosage form of claim 60~~47~~, wherein the period of time is more than 1 hour.

73. (previously presented) The dosage form of claim 72, wherein the period of time is more than 2 hours.

74. (previously presented) The dosage form of claim 73, wherein the period of time is from 2 hours to 24 hours.

75. (previously presented) The dosage form of claim 60, wherein the release of cilostazol and solubilizer are synchronized with a correlation coefficient of greater than 0.80.

76. (previously presented) The dosage form of claim 60, including one or more additives.

77. (previously presented) The dosage form of claim 60, wherein the solubilizer is d-α-tocopherol polyethylene glycol 1000 succinate and the release modulator is α-tocopherol succinate.

78. (previously presented) The dosage form of claim 77 including one or more additives.

79 (previously presented) The dosage form of claim 78, wherein the solubilizer is d-α-tocopherol polyethylene glycol 1000 succinate, the release modulator is α-tocopherol succinate and the additive is polyethylene glycol.

80. (previously presented) The dosage form of claim 60, wherein the solubilizer is polyoxyl 40

hydrogenated castor oil and the release modulator is hydroxypropylmethylcellulose.

81. (previously presented) The dosage form of claim 60, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is glycerol dibehenate, glycerol palmitostearate, glycerol distearate, or mixtures thereof.

82. (previously presented) The dosage form of claim 60, wherein the release modulator is the same compound as the solubilizer.